Order Mounjaro (tirzepatide) Online For Weight Loss Treatment In Canada, USA & Australia With Or Without Prescription
Tirzepatide, a drug approved for the treatment of type 2 diabetes, could be on its way to becoming a new drug to treat obesity as well, now that the U.S. Food and Drug Administration (FDA) has granted it a Fast Track designation.
Marketed for type 2 diabetes as Mounjaro, the drug can lead to dramatic weight loss and a significant reduction in A1C, or average blood sugar levels, in people with type 2 diabetes. Mounjaro is now commercially available for that group, says Maggie Pfeiffer, the associate director of Lilly Diabetes Communications (Eli Lilly and Company manufactures the drug). This once-weekly injection was approved by the FDA as a new class of medication for people with type 2 diabetes on May 13, 2022.
On October 6, 2022, Eli Lilly announced in a press release that the FDA had given Fast Track designation to tirzepatide as a potential treatment for people with weight-related health diagnoses such as obesity and overweight. This designation allows Lilly to complete an application for FDA approval of tirzepatide for this new indication on a rolling basis, as it conducts additional research, rather than complete the application all at once. If results of Lilly’s trial are favorable, the Fast Track designation could mean a quicker FDA approval of tirzepatide for obesity and overweight, and possibly a faster entry to market, the company notes in its release. Lilly also said that its research, part of a trial called SURMOUNT-2, may be completed by late April 2023.
The news follows early speculation from experts that Mounjaro could be rebranded as an obesity drug, after study results revealed the weight loss potential of the drug in people with type 2 diabetes and obesity, and obesity independent of a type 2 diabetes diagnosis.
Some of the initial public interest around tirzepatide for weight loss was piqued at the American Diabetes Association (ADA) Scientific Sessions on June 4, 2022, where researchers reported the aforementioned findings — namely that about 9 out of 10 people with obesity, but without diabetes, lost weight when taking tirzepatide. The randomized controlled trial involved 2,539 adults who had a BMI of 38, signifying obesity, and weighed an average of 231 pounds. When people took the highest dose of tirzepatide in the study, 15 milligrams (mg), they lost an average of about 21 percent of their body weight, or nearly 52 pounds, researchers reported. These findings of the SURMOUNT-1 clinical trial were simultaneously published in the New England Journal of Medicine July 21, 2022.
“It was very exciting to hear that this became approved [for type 2 diabetes],” says Robert Gabbay, MD, PhD, the chief science and medical officer for the ADA, in Arlington, Virginia, speaking about tirzepatide’s approval as a type 2 diabetes medication.